Targeted drug shows promise for rare cancers with ROS1 mutation
NCT ID NCT04439253
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tested the drug crizotinib in 4 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called ROS1 translocation. The drug blocks a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is a small, early-phase study to gather information on how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.